Want to see CH:MED full AI Analyst Report?
MED Stock Chart & Stats
CHF88.20
-CHF0.80(-1.09%)
At close: 4:00 PM EST
CHF88.20
-CHF0.80(-1.09%)
Day’s Range― - ―
52-Week RangeCHF70.60 - CHF97.50
Previous CloseN/A
Volume945.00
Average Volume (3M)6.38K
Market Cap
CHF1.23B
Enterprise ValueCHF1.04B
Total Cash (Recent Filing)CHF32.97M
Total Debt (Recent Filing)CHF157.72M
Price to Earnings (P/E)134.2
Beta0.94
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.67
Shares Outstanding13,646,113
10 Day Avg. Volume7,172
30 Day Avg. Volume6,381
Financial Highlights & Ratios
PEG Ratio0.95
Price to Book (P/B)3.97
Price to Sales (P/S)4.07
P/FCF Ratio117.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.52
Revenue Forecast (FY)CHF326.20M
Bulls Say, Bears Say
Bulls Say
AcquisitionsThe NeoOrtho acquisition makes sense as many markets struggle with care affordability, offering a way to differentiate the premium Swiss brand while gaining access to volume and scale that large tenders offer.
Growth ExpectationsFY25 guide looks achievable with a 13%-15% organic Sales growth outlook and a more robust EBITDA range in the high-teens guided for FY25.
Product StrategyMore focus on Upper Extremities going forward, where the portfolio is complete, and the Keri Touch thumb device can generate pull-through, is seen as the right approach.
Bears Say
Market ExpectationsTop-line FY25 guidance is approximately 7-9% below consensus, which is causing disappointment despite EBITDA being in line.
Strategic ChallengesManagement referred to issues surrounding client engagement/onboarding, set retrieval/line filling, and management changes and unachievable targets in the U.S.
Medartis Holding AG News
MED FAQ
What was Medartis Holding AG’s price range in the past 12 months?
Medartis Holding AG lowest stock price was CHF70.60 and its highest was CHF97.50 in the past 12 months.
What is Medartis Holding AG’s market cap?
Medartis Holding AG’s market cap is CHF1.23B.
When is Medartis Holding AG’s upcoming earnings report date?
Medartis Holding AG’s upcoming earnings report date is Aug 18, 2026 which is in 34 days.
How were Medartis Holding AG’s earnings last quarter?
Medartis Holding AG released its earnings results on Mar 17, 2026. The company reported CHF0.788 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Medartis Holding AG overvalued?
According to Wall Street analysts Medartis Holding AG’s price is currently Overvalued.
Does Medartis Holding AG pay dividends?
Medartis Holding AG does not currently pay dividends.
What is Medartis Holding AG’s EPS estimate?
Medartis Holding AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medartis Holding AG have?
Medartis Holding AG has 13,646,113 shares outstanding.
What happened to Medartis Holding AG’s price movement after its last earnings report?
Medartis Holding AG reported an EPS of CHF0.788 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.196%.
Which hedge fund is a major shareholder of Medartis Holding AG?
Currently, no hedge funds are holding shares in CH:MED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medartis Holding AG
Medartis Holding AG is a global medical technology firm that develops, manufactures, and distributes implantable solutions. These advanced medical devices are utilized worldwide for the surgical stabilization of bone fractures in both the upper and lower extremities, in addition to addressing complex cranio-maxillofacial surgical needs. The company's portfolio features osteosynthesis instruments, marketed under the APTUS and MODUS brands, specifically designed for various body regions including the hand, wrist, elbow, shoulder, foot, and ankle, as well as for facial and skull procedures involving the mandible, midface, orthognathic structures, and cranium. Medartis serves a diverse clientele comprising surgeons, hospitals, medical centers, and group purchasing organizations. The company, founded in 1997, is headquartered in Basel, Switzerland.
Technical Analysis
Sonova Holding AG
―
Basilea Pharmaceutica
―
Medacta Group SA
―
Siegfried Holding AG
―
Tecan Group AG
―
Options Prices
Currently, No data available
---